康弘药业
(002773)
| 流通市值：134.35亿 | | | 总市值：180.21亿 |
| 流通股本：6.87亿 | | | 总股本：9.21亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,171,579,261.56 | 2,179,163,287 | 1,046,478,561.32 | 4,585,133,789.58 |
| 营业收入 | 3,171,579,261.56 | 2,179,163,287 | 1,046,478,561.32 | 4,585,133,789.58 |
| 二、营业总成本 | 2,243,327,871.73 | 1,522,675,525.42 | 690,570,560.84 | 3,278,743,141.86 |
| 营业成本 | 359,006,480.58 | 250,669,340.27 | 118,653,783.45 | 465,414,594.12 |
| 税金及附加 | 58,979,161.19 | 41,981,787.49 | 18,605,409.32 | 59,059,726.52 |
| 销售费用 | 1,133,944,538.93 | 778,808,522.92 | 367,061,985.03 | 1,721,166,768.03 |
| 管理费用 | 376,726,669.34 | 254,623,065.33 | 111,821,677.94 | 552,780,072.59 |
| 研发费用 | 353,898,333.5 | 225,341,055.07 | 86,772,265.16 | 533,093,330.63 |
| 财务费用 | -39,227,311.81 | -28,748,245.66 | -12,344,560.06 | -52,771,350.03 |
| 其中:利息收入 | 39,847,423.22 | 29,192,730.67 | 12,630,866.48 | 53,345,706.75 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,569,600 | 1,569,600 | 192,600 | 550,600 |
| 加:投资收益 | 9,199,646.01 | 8,361,729.37 | -214,779.77 | 36,236,443.63 |
| 资产处置收益 | -485,407.01 | -61,057.22 | -54,652.96 | 9,782.42 |
| 资产减值损失(新) | -102,047.02 | -108,407.02 | - | -7,560,810.49 |
| 信用减值损失(新) | -4,351,622.06 | -4,353,371.66 | -532,473.98 | -424,902.59 |
| 其他收益 | 15,077,165.09 | 13,388,682.92 | 3,970,171.18 | 42,163,692.87 |
| 四、营业利润 | 949,158,724.84 | 675,284,937.97 | 359,268,864.95 | 1,377,365,453.56 |
| 加:营业外收入 | 766,931.15 | 289,329.77 | 177,945.9 | 17,312,300.77 |
| 减:营业外支出 | 29,166,814.03 | 15,186,930.96 | 934,927.73 | 38,564,204.5 |
| 五、利润总额 | 920,758,841.96 | 660,387,336.78 | 358,511,883.12 | 1,356,113,549.83 |
| 减:所得税费用 | 151,697,127.27 | 105,441,457.93 | 55,308,519.39 | 210,609,936.12 |
| 六、净利润 | 769,061,714.69 | 554,945,878.85 | 303,203,363.73 | 1,145,503,613.71 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 769,061,714.69 | 554,945,878.85 | 303,203,363.73 | 1,145,503,613.71 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 784,055,695.42 | 564,746,237.75 | 307,482,134.44 | 1,162,966,864.98 |
| 少数股东损益 | -14,993,980.73 | -9,800,358.9 | -4,278,770.71 | -17,463,251.27 |
| 扣除非经常损益后的净利润 | 791,756,310.12 | 557,039,123.98 | 304,666,792.77 | 1,117,941,258.68 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.85 | 0.61 | 0.33 | 1.26 |
| (二)稀释每股收益 | 0.85 | 0.61 | 0.33 | 1.26 |
| 八、其他综合收益 | -1,745,237.94 | -1,693,472.61 | 273,714.13 | -126,281.75 |
| 归属于母公司股东的其他综合收益 | -1,745,237.94 | -1,693,472.61 | 273,714.13 | -126,281.75 |
| 九、综合收益总额 | 767,316,476.75 | 553,252,406.24 | 303,477,077.86 | 1,145,377,331.96 |
| 归属于母公司股东的综合收益总额 | 782,310,457.48 | 563,052,765.14 | 307,755,848.57 | 1,162,840,583.23 |
| 归属于少数股东的综合收益总额 | -14,993,980.73 | -9,800,358.9 | -4,278,770.71 | -17,463,251.27 |
| 公告日期 | 2026-10-28 | 2026-08-26 | 2026-04-23 | 2026-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |